Colesevelam: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}}; {{AE}} {{SS}} | {{CMG}}; {{AE}} {{SS}} | ||
Line 13: | Line 12: | ||
==Category== | ==Category== | ||
Bile acid sequestrant | |||
== | ==Prescribing Information== | ||
'' | ===''[[Colesevelam hydrochloride|Colesevelam hydrochloride]]''=== | ||
* [[Welchol]] | |||
{{Lipid modifying agents}} | {{Lipid modifying agents}} | ||
Revision as of 15:46, 26 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Colesevelam, click here.
Synonyms / Brand Names: Welchol®
Overview
Colesevelam is a bile acid sequestrant administered orally. It is developed by Genzyme and marketed in the US by Daiichi Sankyo under the brand name Welchol and elsewhere by Genzyme as Cholestagel. In Canada it is marketed by Valeant as Lodalis.
Category
Bile acid sequestrant